Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients (SUIT-AMI)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2010 by Beijing Anzhen Hospital.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Beijing Anzhen Hospital
ClinicalTrials.gov Identifier:
NCT01181388
First received: August 11, 2010
Last updated: August 12, 2010
Last verified: June 2010

August 11, 2010
August 12, 2010
April 2010
April 2012   (Final data collection date for primary outcome measure)
  • Major adverse cardiovascular events [ Time Frame: 1 month after PCI ]
    Infarct size, reinfarction, motality, et.al.
  • Major adverse cardiovascular events [ Time Frame: 3 months after PCI ]
    Infarct size, reinfarction, motality, et.al.
  • Major Adverse Cardiovascular Events [ Time Frame: 6 months after PCI ]
    Infarct size, reinfarction, motality, et.al.
Same as current
No Changes Posted
number of participants with bleeding events [ Time Frame: 1 month ]
bleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria
Same as current
Not Provided
Not Provided
 
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Myocardial Infarction
  • Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
    a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
  • Procedure: administration of tirofiban by guide catheter
    a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
  • Active Comparator: intra-guide-catheter infusion of tirofiban
    Intervention: Procedure: administration of tirofiban by guide catheter
  • Experimental: intra-thrombus-aspiration-catheter infusion of tirofiban
    Intervention: Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
200
October 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • STEMI patients
  • chest pain for less than 12hr
  • plan to PCI

Exclusion Criteria:

  • LM lesion
  • stent thrombosis
  • cardiac shock
  • thrombocytopenia
  • allergy to asprin
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01181388
64456541
Not Provided
Not Provided
Not Provided
Not Provided
Hongbing Yan, the 28th Division, Beijing Anzhen Hospital
Beijing Anzhen Hospital
Not Provided
Not Provided
Beijing Anzhen Hospital
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP